{"id":857,"date":"2026-05-25T03:49:50","date_gmt":"2026-05-25T03:49:50","guid":{"rendered":"https:\/\/wuhantopmiraclepeptides.com\/?post_type=product&p=857"},"modified":"2026-07-05T11:04:18","modified_gmt":"2026-07-05T11:04:18","slug":"cagrilintide-b5mg-semaglutide-10mg","status":"publish","type":"product","link":"https:\/\/wuhantopmiraclepeptides.com\/index.php\/product\/cagrilintide-b5mg-semaglutide-10mg\/","title":{"rendered":"Cagrilintide B5mg + Semaglutide 10mg"},"content":{"rendered":"

Cagrilintide B5mg + Semaglutide 10mg Research Peptide: A Dual\u2011Mechanism Combination for Metabolic & Obesity Studies<\/span><\/h1>\n

If your research explores complementary pathways in appetite regulation, energy balance, and glycaemic control, the Cagrilintide B5mg + Semaglutide 10mg<\/strong><\/span>\u00a0<\/strong>research peptide<\/span><\/strong>\u00a0offers a precisely formulated, dual\u2011mechanism experimental platform. This fixed\u2011dose combination, known in clinical research as\u00a0<\/span>CagriSema<\/span><\/strong>, unites two well\u2011characterised peptide therapeutics with distinct yet complementary modes of action. Cagrilintide is a long\u2011acting amylin and calcitonin receptor agonist (a DACRA) that induces satiety through brainstem pathways<\/span>, while semaglutide is a potent GLP\u20111 receptor agonist that reduces food intake and improves glycaemic control Cagrilintide B5mg + Semaglutide 10mg <\/span>. <\/span><\/p>\n

By targeting both the amylin\/calcitonin system and the incretin pathway, this combination allows researchers to model the synergistic interplay that governs appetite suppression and metabolic regulation, providing deeper insight into the regulatory circuits that drive weight loss and glycaemic improvement.<\/span><\/p>\n

At\u00a0<\/span>Wuhan Top Miracle Peptides<\/span><\/strong>, we supply high\u2011purity Cagrilintide B5mg + Semaglutide 10mg<\/strong><\/span>\u00a0research peptide<\/span><\/strong>\u00a0to research institutions and wholesale buyers across the\u00a0<\/span>United Kingdom, France, Germany, Spain, Sweden, Italy, and the USA<\/span><\/strong>. Every batch is lyophilised, HPLC\u2011verified to \u226598% purity, and accompanied by a Certificate of Analysis (COA), ensuring your investigations into metabolic regulation, satiety signalling, and obesity research begin with uncompromising quality.<\/span><\/p>\n

What Is the Cagrilintide B5mg + Semaglutide 10mg Combination and How Does It Work?<\/span><\/h2>\n

To fully appreciate the research potential of the Cagrilintide B5mg + Semaglutide 10mg<\/strong><\/span>\u00a0research peptide<\/span><\/strong>, it is essential to understand the distinct yet complementary mechanisms of its two components.<\/span><\/p>\n

Cagrilintide: The Dual Amylin & Calcitonin Receptor Agonist (DACRA)<\/span><\/h3>\n

Cagrilintide (AM833) is a long\u2011acting, lipidated analogue of the pancreatic hormone amylin. It is engineered as a\u00a0<\/span>dual amylin and calcitonin receptor agonist (DACRA)<\/span><\/strong>, binding non\u2011selectively to amylin receptors (AMY1R, AMY2R, AMY3R) and the calcitonin receptor (CTR)<\/span>. Cryo\u2011EM structural studies reveal that cagrilintide adopts a distinct \u201cbypass\u201d binding mode, anchored at the receptor transmembrane bundle level by key residues including F23Cagri<\/span>.<\/span><\/p>\n

Mechanism of Action:<\/span><\/strong>\u00a0Cagrilintide activates Gs\u2011coupled signalling pathways through both CTR and AMY1R, increasing intracellular cAMP<\/span>. It exerts its effects on energy balance through the dorsal vagal complex (DVC) of the brainstem, where long\u2011term treatment upregulates prolactin\u2011releasing hormone (Prlh) expression in Calcr\/Prlh neurons<\/span>. This neural pathway mediates satiety and reduces food intake. In preclinical studies, cagrilintide induces\u00a0<\/span>11.8% weight loss<\/span><\/strong>\u00a0over 68 weeks as monotherapy<\/span>.<\/span><\/p>\n

Semaglutide: The GLP\u20111 Receptor Agonist<\/span><\/h3>\n

Semaglutide is a well\u2011established GLP\u20111 receptor agonist with proven weight\u2011loss and cardiovascular benefits at a dose of 2.4 mg<\/span>. It reduces appetite, delays gastric emptying, and improves glycaemic control through GLP\u20111 receptor activation.<\/span><\/p>\n

Mechanism of Synergy: Dual\u2011Pathway Satiety Signalling<\/span><\/h3>\n

The scientific rationale for combining cagrilintide and semaglutide lies in their convergent yet distinct mechanisms:<\/span><\/p>\n

    \n
  • \n

    Cagrilintide<\/span><\/strong>\u00a0targets the amylin\/calcitonin system, activating brainstem pathways that induce satiety and reduce food intake through a non\u2011incretin mechanism<\/span>.<\/span><\/p>\n<\/li>\n

  • \n

    Semaglutide<\/span><\/strong>\u00a0targets the GLP\u20111 system, reducing appetite, improving glycaemic control, and promoting weight loss through well\u2011characterised incretin pathways<\/span>.<\/span><\/p>\n<\/li>\n

  • \n

    Distinct Mechanisms:<\/span><\/strong>\u00a0CagriSema reduces energy intake and appetite without significantly delaying gastric emptying<\/span>, suggesting that the two components work through complementary rather than redundant pathways.<\/span><\/p>\n<\/li>\n

  • \n

    Greater Efficacy:<\/span><\/strong>\u00a0In the phase 3 REDEFINE 1 trial (3417 participants without diabetes), CagriSema (2.4 mg each) achieved a\u00a0<\/span>20.4% mean weight loss<\/span><\/strong>\u00a0at week 68 compared to 3.0% with placebo \u2014 an estimated difference of 17.3 percentage points<\/span>. In the REDEFINE 2 trial (1206 participants with type 2 diabetes), CagriSema resulted in\u00a0<\/span>13.7% weight loss<\/span><\/strong>\u00a0compared to 3.4% with placebo<\/span>.<\/span><\/p>\n<\/li>\n<\/ul>\n

    Key Research Applications for Cagrilintide + Semaglutide<\/span><\/h2>\n

    The Cagrilintide B5mg + Semaglutide 10mg<\/strong><\/span>\u00a0research peptide<\/span><\/strong>\u00a0is a versatile tool with applications spanning several domains of biomedical research.<\/span><\/p>\n

    1. Obesity & Metabolic Research<\/span><\/h3>\n

    As a dual\u2011mechanism combination that induces significant weight loss through satiety signalling, this blend is a valuable tool for studying obesity pathophysiology. Research applications include:<\/span><\/p>\n